Madrigal Pharmaceuticals just watched its stock price fall off a cliff, dropping over 11% in a single morning despite reporting a staggering 210% revenue growth. How does a company generate $321 million in a quarter—with a drug on track to be a billion-dollar blockbuster—and still see its valuation shredded?

In this episode of Implied, we dig into the disconnect between Madrigal’s dominant market position with Rezdiffra and the investor panic triggered by a slight earnings miss and "seasonal" warnings. We break down the red flags that Wall Street can’t ignore: high-level insiders offloading millions in shares, the looming shadow of giants like Novo Nordisk, and a "burn now, earn later" model that is losing its luster. Is this an overreaction to a powerhouse in the making, or a warning sign  ...